Antares Therapeutics

Antares Therapeutics

CA - South SF
Biotechnology2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecule Technologies

Antares Therapeutics is a life sciences company focused on Small Molecule Technologies.

EndocrinologyImmunologyOncologyNeurologyGastroenterology
Funding Stage
PUBLIC
Open Jobs
1

Products & Portfolio (1)

1 discontinued product not shown

XYOSTED (AUTOINJECTOR)
testosterone enanthate
Peak
SUBCUTANEOUS · SOLUTION
2018
0

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT04879589Phase 1 Study of ATRS-2002 in Healthy Male Adults
Phase 1
Testosterone enanthate auto-injector
Hypogonadism
Phase 1
Clinical Trials (1)
NCT02233751Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
Phase 1
QuickShot™ - 50 mg Treatment B
Hypogonadism
Phase 1/2
Clinical Trials (1)
NCT01887418Pharmacokinetic Study of Testosterone Enanthate
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01737944Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration
Phase 1/2
Phase 2
Clinical Trials (1)
NCT01618968Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
Phase 2
Testosterone enanthate auto-injector
Hypogonadism
Phase 2
Clinical Trials (1)
NCT02777242Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
Phase 2
Phase 2
Clinical Trials (1)
NCT01618955Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
Phase 2
Phase 3
Clinical Trials (1)
NCT00909181Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Phase 3
Testosterone enanthate auto-injector
Hypogonadism
Phase 3
Clinical Trials (1)
NCT02504541Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
Phase 3
Testosterone enanthate auto-injector
Hypogonadism
Phase 3
Clinical Trials (1)
NCT02159469Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
Phase 3
XYOSTED 75 milligram
Multiple Sclerosis
Phase 4
Clinical Trials (1)
NCT04601233Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Phase 4

Open Jobs (1)

Principal Scientist, Formulation Development (Small Molecules)

Boston, MA
Research & Development
1mo ago
$160K - $220K/yr
Interview Prep Quick Facts
Portfolio: 2 approved products, 11 clinical trials
H-1B (2023): 2 approvals
Open Roles: 1 active job
Portfolio Health
Peak1 (50%)
Post-LOE1 (50%)
2 total products

Hiring Trend

Stable
1
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub